Exerenibart Biosimilar Monoclonal Antibody (Matriptase-2) for Research

Cat No.: GMP-Bios-INN-1196

Anti-TMPRSS6/MT2 therapeutic antibody (Pre-made Exerenibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Exerenibart (development code REGN-7999) is a human monoclonal antibody targeting TMPRSS6 (matriptase-2). It is developed by Regeneron Pharmaceuticals for beta-thalassemia. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1196-1mg 1mg 3090
GMP-Bios-INN-1196-10mg 10mg
GMP-Bios-INN-1196-100mg 100mg
GMP-Bios-INN-1196-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Exerenibart biosimilar, Whole mAb, Anti-TMPRSS6/MT2 Antibody: Anti-TMPRSS6/Transmembrane protease serine 6/Matriptase-2/MT2 therapeutic antibody
INN Name Exerenibart
Target TMPRSS6/MT2
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC